122 related articles for article (PubMed ID: 14644513)
1. Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models.
Cook JW; Sterman DH; Singhal S; Smythe WR; Kaiser LR
Lung Cancer; 2003 Dec; 42(3):263-74. PubMed ID: 14644513
[TBL] [Abstract][Full Text] [Related]
2. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
Chahinian AP; Mandeli JP; Gluck H; Naim H; Teirstein AS; Holland JF
J Surg Oncol; 1998 Feb; 67(2):104-11. PubMed ID: 9486781
[TBL] [Abstract][Full Text] [Related]
5. Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Westermann AM; Dubbelman R; Moolenaar WH; Beijnen J; Rodenhuis S
Ann Oncol; 1997 Aug; 8(8):801-2. PubMed ID: 9332690
[No Abstract] [Full Text] [Related]
6. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma.
Miselis NR; Wu ZJ; Van Rooijen N; Kane AB
Mol Cancer Ther; 2008 Apr; 7(4):788-99. PubMed ID: 18375821
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
8. The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis.
Colson YL; Liu R; Southard EB; Schulz MD; Wade JE; Griset AP; Zubris KA; Padera RF; Grinstaff MW
Biomaterials; 2011 Jan; 32(3):832-40. PubMed ID: 21044799
[TBL] [Abstract][Full Text] [Related]
9. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Davol PA; Garza S; Frackelton AR
Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546
[TBL] [Abstract][Full Text] [Related]
10. Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.
Mezzapelle R; Rrapaj E; Gatti E; Ceriotti C; Marchis FD; Preti A; Spinelli AE; Perani L; Venturini M; Valtorta S; Moresco RM; Pecciarini L; Doglioni C; Frenquelli M; Crippa L; Recordati C; Scanziani E; de Vries H; Berns A; Frapolli R; Boldorini R; D'Incalci M; Bianchi ME; Crippa MP
Sci Rep; 2016 Mar; 6():22850. PubMed ID: 26961782
[TBL] [Abstract][Full Text] [Related]
11. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
[TBL] [Abstract][Full Text] [Related]
12. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
Kruklitis RJ; Singhal S; Delong P; Kapoor V; Sterman DH; Kaiser LR; Albelda SM
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):123-30. PubMed ID: 14752422
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
14. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
Nici L; Monfils B; Calabresi P
Clin Cancer Res; 2004 Nov; 10(22):7655-61. PubMed ID: 15569998
[TBL] [Abstract][Full Text] [Related]
15. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
16. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
17. Effect of suramin on human esophageal cancer cells in vitro and in vivo.
Shin R; Naomoto Y; Kamikawa Y; Tanaka N; Orita K
Scand J Gastroenterol; 1997 Aug; 32(8):824-8. PubMed ID: 9282976
[TBL] [Abstract][Full Text] [Related]
18. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
19. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
[TBL] [Abstract][Full Text] [Related]
20. Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines.
Sandgren S; Belting M
Anticancer Res; 2003; 23(2B):1223-8. PubMed ID: 12820375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
